Boston Scientific Corporation (N:BSX)

Business Focus: Advanced Medical Equipment & Technology

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEC
Company Contact
Address: 300 Boston Scientific Way
MARLBOROUGH MA 01752-1291
Tel: N/A
Website: https://www.bostonscientific.com/en-US/Home.html
IR: See website
<
Key People
Michael F. Mahoney
Chairman of the Board, President, Chief Executive Officer
Emily Woodworth
Senior Vice President, Chief Accounting Officer, Controller
Daniel J. Brennan
Chief Financial Officer, Executive Vice President
Wendy Carruthers
Executive Vice President - Human Resources
Arthur Crosswell Butcher
Executive Vice President, Group President, MedSurg and Asia Pacific
Joseph M. Fitzgerald
Executive Vice President, Group President - Cardiology
Ian T. Meredith
Executive Vice President, Global Chief Medical Officer
Jeffrey B. Mirviss
Executive Vice President and President - Peripheral Interventions
John Bradley Sorenson
Executive Vice President - Global Operations
Eric Francis Yves Thepaut
Executive Vice President and President - Europe, Middle East and Africa
   
Business Overview
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's segments include MedSurg and Cardiovascular. The MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. The Cardiovascular segment includes Cardiology and Peripheral Interventions. The Company's Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions.
Financial Overview
For the fiscal year ended 31 December 2023, Boston Scientific Corporation revenues increased 12% to $14.24B. Net income applicable to common stockholders increased from $642M to $1.57B. Revenues reflect Cardiovascular segment increase of 13% to $8.82B, MedSurg segment increase of 10% to $5.42B, United States segment increase of 10% to $8.43B, EMEA (Europe, Middle East and Africa) segment increase of 13% to $2.86B.
Employees: 48,000 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $109,101M as of Dec 31, 2023
Annual revenue (TTM): $14,240M as of Dec 31, 2023
EBITDA (TTM): $4,079M as of Dec 31, 2023
Net annual income (TTM): $1,571M as of Dec 31, 2023
Free cash flow (TTM): $1,764M as of Dec 31, 2023
Net Debt Last Fiscal Year: $8,237M as of Dec 31, 2023
Shares outstanding: 1,469,895,391 as of Mar 8, 2024
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.